Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of respiratory diseases with significant unmet medical needs. Their lead product candidate, ensifentrine, is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently advancing ensifentrine through late-stage clinical development for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and is also exploring its potential in asthma and cystic fibrosis.
Serves as the registered office and central hub for corporate governance, strategic decision-making, financial oversight, and global clinical development strategy.
Located in the modern More London development, offering a professional environment with access to key business services and transport links. The focus is on functional, collaborative office space.
A dynamic, science-driven, and patient-focused environment. Emphasis on collaboration, innovation, and achieving clinical milestones in respiratory medicine. The culture supports a lean and agile operational model.
The London headquarters is key for global strategy, investor relations (being listed on Nasdaq), and European regulatory interactions. It anchors the company's international identity.
While Verona Pharma's main physical offices are in the UK and USA, its operational reach is global. The company conducts multinational clinical trials for its drug candidates, involving research sites and patients across North America and Europe. This global approach is essential for developing therapies for widespread conditions like COPD and for seeking regulatory approvals in multiple major markets.
3 More London Riverside
London
England
United Kingdom
Address: One Copley Parkway, Suite 460, Morrisville, NC 27560, USA
To lead and support the clinical advancement and future market access of ensifentrine in the largest pharmaceutical market, the U.S., and to engage with key stakeholders in the North American respiratory disease community.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Verona Pharma' leadership includes:
Verona Pharma has been backed by several prominent investors over the years, including:
In the past year, Verona Pharma plc has strengthened its executive team with a key appointment to lead business development efforts, underscoring its focus on strategic growth and commercial preparedness. There have been no major departures announced from the core executive leadership during this period.
Discover the tools Verona Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Verona Pharma plc likely utilizes common corporate email formats. While the exact primary format isn't publicly disclosed, typical structures for companies of its size and nature include first initial followed by last name, or first name dot last name, using the @veronapharma.com domain.
[firstinitial][lastname]@veronapharma.com or [first].[lastname]@veronapharma.com
Format
dzaccardelli@veronapharma.com
Example
85%
Success rate
GlobeNewswire (Verona Pharma plc Press Release) • May 9, 2024
Verona Pharma reported its financial results for the first quarter of 2024, highlighted progress with its New Drug Application (NDA) submission for ensifentrine for COPD, and outlined upcoming milestones, including the PDUFA target action date of June 26, 2024....more
GlobeNewswire (Verona Pharma plc Press Release) • March 5, 2024
The company announced its full-year 2023 financial results, detailed the successful NDA submission to the FDA for ensifentrine, and discussed ongoing preparations for a potential U.S. launch for the maintenance treatment of COPD....more
Fierce Biotech • January 2, 2024
The U.S. Food and Drug Administration (FDA) accepted Verona Pharma's New Drug Application (NDA) for ensifentrine for the maintenance treatment of patients with COPD. The FDA granted Priority Review for the application and assigned a PDUFA target action date of June 26, 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Verona Pharma, are just a search away.